$186.65▲ 12.25 (7.02%)
Real-time prices · US MarketsHigh-quality business with 22% return on equity and 17% profit margins.
limited growth momentum.
Quality
8.2
Health
5.7
Growth
5.4
Valuation
7.5
Sentiment
7.3
Analyst Target
$206.66
▲ +10.7% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
27.9×
price-to-earnings
Forward P/E
16.5×
next 12 months est.
Market Cap
$289.5B
market capitalization
Div Yield
1.84%
dividend yield
Profit Margin
17.0%
net profit margin
Gross Margin
81.7%
revenue minus COGS
ROE
22.0%
return on equity
Beta
0.21
vs S&P 500
52-Week Range
$153 — $213
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about AstraZeneca PLC right now?
AstraZeneca PLC's Q·Score is 6.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 22% return on equity and 17% profit margins. Key area to monitor: limited growth momentum. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for AZN?
The consensus price target for AZN is $206.66, based on ratings from 12 Wall Street analysts. This is 10.7% above the current price of $186.65. Price targets are forward-looking estimates and not guarantees of future performance.
Is AZN overvalued or undervalued?
AstraZeneca PLC (AZN) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 16.5×. The consensus analyst price target of $206.66 is 11% above the current price.
What is AstraZeneca PLC's profit margin?
AstraZeneca PLC has a net profit margin of 17.0%, which is solid for most industries. Its gross margin stands at 81.7%, indicating a high-margin business model.
What is AZN's dividend yield?
AstraZeneca PLC currently offers a dividend yield of 1.84%, a modest payout typical for growth-oriented companies. Dividend yields can change based on price movements and company payout decisions.
Is AstraZeneca PLC's revenue growing?
AstraZeneca PLC is reporting modest revenue growth of 6.4%. Earnings are also growing at 2.5%, indicating improving profitability.
How much debt does AstraZeneca PLC have?
AstraZeneca PLC has a debt-to-equity ratio of 0.64×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 0.89×, suggesting it should be monitored for near-term liquidity.